Biotechnology company Novavax says a new study shows that its coronavirus vaccine turns out to be effective against all variants. The study, conducted in the United States and Mexico, involved nearly 30,000 people. According to results published Monday, the vaccine was 90% effective.
US company Novavax announced on Monday that its coronavirus vaccine turns out to be 90.4% effective. In studies involving nearly 30,000 people, 77 individuals became infected with the coronavirus, 14 of them in the vaccinated group and the rest in the unvaccinated group.
“The main results from the study show an efficiency of 90% in general. This is a high figure, as there were many variants of the virus in circulation during clinical trials. “, said Stanley Erck, CEO of the company.
According to the company, the vaccine is effective against all variants. It also offers protection against those who develop moderate and severe symptoms of the disease. The company had previously published data from studies in Britain and South Africa.
The long-awaited results in the United States come as domestic demand for vaccines has dropped dramatically, leaving many cities with an overdose.
About 64% of adults in the US have received at least one dose, while 54% have been fully vaccinated, according to the Centers for Disease Control and Prevention.
However, many countries in the world are trying to vaccinate their inhabitants and have pinned their hopes on different vaccines.
“Vaccines need to be spread globally, especially in low- and middle-income countries. “Our vaccine is particularly suitable, as it is stable at ordinary refrigerator temperatures.”, says CEO Stanley Erck.
During the third quarter of the year, Novavax plans to apply for authorization for emergency use of the vaccine in the United States and other countries.
The Maryland-based company had previously announced delays in the vaccine production process and expects to produce 100 million doses per month by the end of the third quarter and 150 million doses per month by the fourth quarter.